Theriva™ biologics to discuss the trial design for virage - a phase 2b clinical study of systemically administered vcn-01 in combination with chemotherapy in pancreatic ductal adenocarcinoma - at the 2024 american society of clinical oncology (asco) annual meeting

Rockville, md., april 25, 2024 (globe newswire) -- theriva™ biologics (nyse american: tovx), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, virage - the phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered vcn-01 in combination with standard-of-care (soc) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (pdac) - has been accepted for presentation as a trial-in-progress poster at the 2024 american society of clinical oncology (asco) annual meeting, being held in chicago, il, from may 31-june 4.
TOVX Ratings Summary
TOVX Quant Ranking